Home Cart Sign in  
Chemical Structure| 2226664-93-1 Chemical Structure| 2226664-93-1

Structure of KY19382
CAS No.: 2226664-93-1

Chemical Structure| 2226664-93-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

KY19382 is an orally active dual inhibitor targeting CXXC5-DVL and GSK3β, capable of activating the Wnt/β-catenin signaling pathway, showing potential in metabolic disease research.

Synonyms: A3051

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of KY19382

CAS No. :2226664-93-1
Formula : C17H11Cl2N3O2
M.W : 360.19
SMILES Code : O=C1NC=2C=C(Cl)C(Cl)=CC2C1=C3NC=4C=CC=CC4C3=NOC
Synonyms :
A3051
MDL No. :MFCD32878265

Safety of KY19382

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P264-P280-P337+P313-P305+P351+P338-P302+P352-P332+P313-P362

Related Pathways of KY19382

PI3K-AKT
Hedgehog

Isoform Comparison

Biological Activity

Description
KY19382 is a potent dual inhibitor of CXXC5-DVL and GSK3β, exhibiting IC50s of 19 and 10 nM, respectively. It activates Wnt/β-catenin signaling by inhibiting both the CXXC5-DVL interaction and GSK3β activity. KY19382 is suitable for investigating high fat diet (HFD)-induced metabolic diseases[1][2].

In Vitro:

Cell Line
Concentration Treated Time Description References
Human Dermal Fibroblasts (HDFs) 0.1 mM 24 hours KY19382 induces HDFs activation by inhibiting CTBP1 transcription to stabilize β-catenin. Cell Commun Signal. 2025 Feb 25;23(1):108
Human Umbilical Vein Endothelial Cells (HUVECs) 0.1 mM 24 hours KY19382 promotes HUVECs migration and proliferation by inhibiting CTBP1 transcription to release NFκB. Cell Commun Signal. 2025 Feb 25;23(1):108
HaCaT human keratinocytes 1 µM 72 hours To assess the effect of KY19382 on HaCaT cell proliferation. Results showed that the combination treatment of KY19382 with TEPP-46 significantly increased cell proliferation. Pharmaceutics. 2023 Jul 27;15(8):2028
Human dermal fibroblasts (HDFa) 0.1 μM and 1 μM 24 hours KY19382 significantly enhanced the migration of human dermal fibroblasts by activating the Wnt/β-catenin signaling pathway, increasing the levels of β-catenin, Collagen I, and α-SMA. Int J Mol Sci. 2023 Jul 21;24(14):11742
Human keratinocytes (HaCaT) 0.1 μM and 1 μM 24 hours KY19382 significantly enhanced the migration of human keratinocytes by activating the Wnt/β-catenin signaling pathway, increasing the levels of β-catenin, phalloidin, Keratin 14, and PCNA. Int J Mol Sci. 2023 Jul 21;24(14):11742
C28/I2 cells 0.1 μM KY19382 upregulated mRNA levels of chondrogenic markers, promoting chondrocyte differentiation via activation of Wnt/β-catenin signaling. Life Sci Alliance. 2019 Apr 10;2(2):e201800254
ATDC5 cells 0.1 μM 48 hours KY19382 promoted chondrocyte proliferation and differentiation by activating Wnt/β-catenin signaling through inhibition of CXXC5-DVL interaction and GSK3β activity. Life Sci Alliance. 2019 Apr 10;2(2):e201800254
NCI-H441 1 μM 24 hours KY19382 significantly restored proliferation activity of LUAD cells, reduced cell apoptosis, and reduced cell cycle arrest Eur J Med Res. 2025 Apr 1;30(1):221
NCI-H1395 1 μM 24 hours KY19382 significantly restored proliferation activity of LUAD cells, reduced cell apoptosis, and reduced cell cycle arrest Eur J Med Res. 2025 Apr 1;30(1):221
HaCaT human keratinocytes 1 µM 24 hours To assess the effect of KY19382 on HaCaT cell migration. Results showed that the combination treatment of KY19382 with TEPP-46 significantly increased cell migration. Pharmaceutics. 2023 Jul 27;15(8):2028

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Diabetic mouse model Intradermal injection 1 mM Injected on days 0, 2, 4, 6, 8, and 10, lasting for 10 days KY19382 promotes wound healing in diabetic mice by activating the Wnt/β-catenin signaling pathway. Cell Commun Signal. 2025 Feb 25;23(1):108
C3H mice Acute wound healing model Topical application 1 mM Daily application for 14 days To assess the effect of KY19382 on wound healing in mice. Results showed that the combination treatment of KY19382 with TEPP-46 significantly accelerated wound healing, increased re-epithelialization and collagen deposition. Pharmaceutics. 2023 Jul 27;15(8):2028
C3H mice Full-thickness cutaneous wound model Topical application 0.05 mM and 0.1 mM Daily for 12 days KY19382 significantly accelerated cutaneous wound healing, enhancing re-epithelialization, collagen deposition, and expression of stem cell markers (CD34 and Nestin) via activation of the Wnt/β-catenin signaling pathway. Int J Mol Sci. 2023 Jul 21;24(14):11742
Mice Adolescent mice Intraperitoneal injection 0.1 mg/kg Daily for 2 weeks or 10 weeks KY19382 significantly elongated tibial length by delaying growth plate senescence and further activating the growth plate, promoting longitudinal bone growth. Life Sci Alliance. 2019 Apr 10;2(2):e201800254
C57BL/6N mice Depilation-induced hair cycle model Topical administration 0.5 mM Daily administration for 14 or 28 days To evaluate the effect of combined treatment with KY19382 and TEPP-46 on hair regrowth, results showed that the combined treatment significantly enhanced hair regrowth and hair follicle neogenesis. Pharmaceutics. 2022 Dec 13;14(12):2774

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.78mL

0.56mL

0.28mL

13.88mL

2.78mL

1.39mL

27.76mL

5.55mL

2.78mL

References

 

Historical Records

Categories